Statement on the impact of coronavirus disease COVID-19 on our operations

Company news

The novel coronavirus disease Covid-19 first reported in Wuhan, China in late 2019 has spread far beyond China, and now affects approximately 200 countries.

At Fujirebio Europe’s Belgian facilities, we are taking steps to protect our employees, and encourage those who can do so to work from home.  The manufacture of medical products is considered an essential service in Belgium, and our production, quality, and logistics staff continue to work as before.  We have adequate inventories of raw materials to continue uninterrupted manufacturing operations of the INNO-LIA, INNO-LiPA, and INNOTEST product lines for many months. 

We also do not foresee Serodia or Lumipulse manufacturing shortfalls from our Japanese operation. 

However, we are observing that air freight in particular is becoming more complex and more expensive as the number of operational flights drops. 

Since our ability to ship product promptly is less certain than usual, we urge customers to anticipate their needs as far in advance as possible to better facilitate on-time delivery.

We wish all of our customers and their families good health during this unusual and challenging time.


Christiaan De Wilde  Kurt Troch
On behalf of CDW Invest BV
Director Operations